NitazoxanideCAS# 55981-09-4 |
- Azelnidipine
Catalog No.:BCC4400
CAS No.:123524-52-7
- Verapamil HCl
Catalog No.:BCC4747
CAS No.:152-11-4
- Gabapentin HCl
Catalog No.:BCC4502
CAS No.:60142-95-2
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 55981-09-4 | SDF | Download SDF |
| PubChem ID | 41684 | Appearance | Powder |
| Formula | C12H9N3O5S | M.Wt | 307.28 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | NTZ; NSC 697855 | ||
| Solubility | DMSO : ≥ 100 mg/mL (325.44 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate | ||
| SMILES | CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] | ||
| Standard InChIKey | YQNQNVDNTFHQSW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC50 for canine influenza virus ranges from 0.17 to 0.21 μM).
Target: Others
Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. In vitro studies demonstrated much broader activity. Dr. Rossignol co-founded Romark Laboratories, with the goal of bringing nitazoxanide to market as an anti-parasitic drug. Initial studies in the USA were conducted in collaboration with Unimed Pharmaceuticals, Inc. (Marietta, GA) and focused on development of the drug for treatment of cryptosporidiosis in AIDS.
The anti-protozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme dependent electron transfer reaction which is essential to anaerobic energy metabolism. It has also been shown to have activity against influenza A virus in vitro. The mechanism appears to be by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion. This impairs hemagglutinin intracellular trafficking and insertion of the protein into the host plasma membrane. References: | |||||
Nitazoxanide Dilution Calculator
Nitazoxanide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2544 mL | 16.2718 mL | 32.5436 mL | 65.0872 mL | 81.359 mL |
| 5 mM | 0.6509 mL | 3.2544 mL | 6.5087 mL | 13.0174 mL | 16.2718 mL |
| 10 mM | 0.3254 mL | 1.6272 mL | 3.2544 mL | 6.5087 mL | 8.1359 mL |
| 50 mM | 0.0651 mL | 0.3254 mL | 0.6509 mL | 1.3017 mL | 1.6272 mL |
| 100 mM | 0.0325 mL | 0.1627 mL | 0.3254 mL | 0.6509 mL | 0.8136 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nitazoxanide is an antiprotozoal (cryptosporidium), and an anthelmintic (cestodes). This compound is effective against tuberculosis.
- ARC 239 dihydrochloride
Catalog No.:BCC6851
CAS No.:55974-42-0
- Pseudohypericin
Catalog No.:BCN6348
CAS No.:55954-61-5
- Methylpheophorbide A
Catalog No.:BCN7998
CAS No.:5594-30-9
- Betamethasone 17,21-dipropionate
Catalog No.:BCC8875
CAS No.:5593-20-4
- Pennogenin 3-O-beta-chacotrioside
Catalog No.:BCN6707
CAS No.:55916-52-4
- Polyphyllin VI
Catalog No.:BCN1053
CAS No.:55916-51-3
- Cucurbitacin R
Catalog No.:BCN7877
CAS No.:55903-92-9
- Friedelin
Catalog No.:BCN5747
CAS No.:559-74-0
- beta-Amyrin
Catalog No.:BCN5746
CAS No.:559-70-6
- Morolic acid
Catalog No.:BCN7475
CAS No.:559-68-2
- 6-Hydroxysugiol
Catalog No.:BCN3154
CAS No.:55898-07-2
- Boc-D-Lys(Z)-OH
Catalog No.:BCC3423
CAS No.:55878-47-2
- Methylthiouracil
Catalog No.:BCC4800
CAS No.:56-04-2
- 2,4-Diamino-6-hydroxypyrimidine
Catalog No.:BCC6658
CAS No.:56-06-4
- 4-Aminobutanoic acid
Catalog No.:BCN2187
CAS No.:56-12-2
- Cystamine dihydrochloride
Catalog No.:BCC6344
CAS No.:56-17-7
- Cantharidin
Catalog No.:BCN1280
CAS No.:56-25-7
- Tetraethylammonium chloride
Catalog No.:BCC7554
CAS No.:56-34-8
- H-Gly-OH
Catalog No.:BCC2946
CAS No.:56-40-6
- H-Ala-OH
Catalog No.:BCC3190
CAS No.:56-41-7
- H-Ser-OH
Catalog No.:BCC3028
CAS No.:56-45-1
- Deoxycorticosterone acetate
Catalog No.:BCC4655
CAS No.:56-47-3
- Diethylstilbestrol
Catalog No.:BCC4900
CAS No.:56-53-1
- Quinidine
Catalog No.:BCC7863
CAS No.:56-54-2
Nitazoxanide in Acute Rotavirus Diarrhea: A Randomized Control Trial from a Developing Country.[Pubmed:28331496]
J Trop Med. 2017;2017:7942515.
Background. Acute diarrhea is one of the leading causes of childhood mortality, with rotavirus being an important pathogen. Nitazoxanide, an antiparasitic agent, has been shown to inhibit rotavirus. Objective. This double-blind, randomized trial was designed to study the role of Nitazoxanide in acute rotavirus diarrhea. Methods. Of 174 children (12 months to 5 years) with acute diarrhea, 50 rotavirus positive cases were randomized. The intervention group received syrup Nitazoxanide twice daily (100 mg in 12-47 months, 200 mg in >/=4 yr) for 3 days along with standard treatment of diarrhea. Duration of diarrhea was the primary outcome measure. Results. The median duration (hrs) of diarrhea (54 versus 80; 95% CI: -26 [-13.2 to -38.8]) and hospitalization (68 versus 90; 95% CI: -22 [-12.98 to -31.02]) was significantly shorter in the Nitazoxanide group. No significant difference was seen in the median duration (hrs) of fever or vomiting or the proportion of children requiring parenteral rehydration. There was no report of any adverse events. Conclusions. Oral Nitazoxanide is effective and safe in the management of acute rotavirus diarrhea in Indian children (CTRI REF/2016/10/012507).
Pharmacokinetics, Metabolism, and Partial Biodistribution of "Pincer Therapeutic" Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles.[Pubmed:28263078]
Mol Pharm. 2017 Apr 3;14(4):1204-1211.
Nitazoxanide (NTZ) induces autophagy in mammalian cells and also has mycobactericidal activity, displaying a two-pronged therapeutic effect, on the host as well as the pathogen. The pharmacokinetics and biodistribution of inhaled NTZ were investigated. Particles containing NTZ in a matrix of PLGA were prepared by spray drying. HPLC and LC-MS/MS methods were developed and validated. Particles were administered as inhalations to mice. Drug concentrations in plasma and tissues were estimated at different time points. Drug loading ( approximately 36%), entrapment efficiency (>90%), and the conversion of NTZ into metabolites in plasma and lung homogenates were assessed satisfactorily by HPLC. NTZ pharmacokinetics and biodistribution following intravenous administration or inhalation were established by LC-MS. NTZ converted into tizoxanide (99% in 30 min) and other metabolites. Pulmonary delivery of NTZ entrapped in particles increased the half-life of the drug by factors of 3, 12, and 200 in the plasma, lung tissue, and alveolar macrophages, respectively. Targeted delivery and prolonged lung retention along with dose sparing of the kidneys was observed upon pulmonary delivery as compared to intravenous administration.
Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats.[Pubmed:28344497]
Saudi Pharm J. 2017 Mar;25(3):413-418.
Background: Although albendazole is the drug-of-choice for the treatment of neurocysticercosis, its efficacy is limited due to its low bioavailability. An alternative for optimizing pharmacological treatment is through drug combinations. In vitro studies have shown that Nitazoxanide and tizoxanide (the active metabolite of Nitazoxanide) exhibit cysticidal activity and that the combination of tizoxanide with albendazole sulfoxide (the active metabolite of albendazole) produced an additive effect. Objectives: (1) To assess the concentration profile of tizoxanide in plasma and in cerebrospinal fluid; and (2) to evaluate the influence of Nitazoxanide on the pharmacokinetics of albendazole in plasma and in cerebrospinal fluid. Methods: Two different studies were conducted. In study 1, 10 male Sprague-Dawley rats received a single oral dose of 7.5 mg/kg of Nitazoxanide and serial blood and cerebrospinal fluid samples were collected over a period of 4 h. In study 2, 38 healthy male Sprague-Dawley rats were randomly divided into two groups: one of these received a single dose of albendazole (15 mg/kg) and, in the other group, albendazole (15 mg/kg) was co-administered with Nitazoxanide (7.5 mg/kg). Plasma and cerebrospinal fluid samples were collected from 0 to 16 h after administration. Albendazole sulfoxide and tizoxanide levels were assayed by using HPLC or LC/MS techniques. Results: In study 1, tizoxanide reached a maximum plasma concentration of 244.42 +/- 31.98 ng/mL at 0.25 h; however, in cerebrospinal fluid, this could be detected only at 0.5 h, and levels were below the quantification limit (10 ng/mL). These data indicate low permeation of tizoxanide into the blood brain barrier. In study 2, Cmax, the area under the curve, and the mean residence time of albendazole sulfoxide in plasma and cerebrospinal fluid were not affected by co-administration with Nitazoxanide. Conclusion: The results of the present study indicate that in rats at the applied doses, tizoxanide does not permeate into the cerebrospinal fluid. Furthermore, Nitazoxanide does not appear to alter significantly the pharmacokinetics of albendazole in plasma or in cerebrospinal fluid.
